CrystalGenomics Submits IND for Phase 2 Clinical Trial Targeting Pancreatic Cancer Patients to US FDA

[Asia Economy Reporter Minji Lee] CrystalGenomics announced on the 20th that it has submitted a clinical phase 2 trial plan to the US FDA to compare the efficacy and safety of ivaltinostat/capecitabine combination therapy and capecitabine monotherapy in patients with metastatic pancreatic cancer.

The company stated, "By administering capecitabine, which is used as maintenance therapy for pancreatic cancer, in combination with ivaltinostat, an anticancer drug candidate with confirmed tolerability and safety, we expect a significantly enhanced anticancer effect," adding, "We believe we can offer better treatment options to pancreatic cancer patients."